ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Symptom distress and fear of progression associated with quality of life in multiple myeloma patients receiving treatment.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposePatients undergoing treatment for multiple myeloma (MM), a common hematological malignancy, may experience symptom distress, functional decline, fear of disease progression, and poor quality of life (QOL). This study of MM patients aims to assess patient-reported symptom distress, functional impairment, fear of cancer progression, and QOL and to identify factors associated with QOL.
methodsThis cross-sectional study used consecutive sampling to recruit subjects from inpatient wards and the outpatient departments of hematology and chemotherapy at a medical center in northern Taiwan. Patients were assessed via self-reported questionnaires for symptom distress, functional impairment, fear of progression (FoP), and QOL. Descriptive analysis, Pearson's product-moment correlation, multiple regression, independent-samples t-test, and one-way ANOVA were used to analyze the data.
resultsA total of 100 MM patients were included in this study. The most common symptoms reported to cause distress during treatment were fatigue, immobility, difficulty defecating, pain, numbness, and insomnia. The greatest level of functional impairment was in the ability to get around. A high level of FoP was reported by 32.0% of the patients. Multiple regression analysis showed that MM patients who had higher performance status, lower symptom distress, and lower FoP were more likely to have higher QOL. These 3 factors accounted for 78.1% of the variance in QOL.
conclusionPerformance status was the greatest predictor of overall QOL and of five QOL domains. Patient-centered care programs that address symptom management, resistance training, diet control, and supportive care during treatment can reduce symptoms and FoP and improve the performance status and QOL of MM patients during treatment.
Indexed as
Identifiers
41222707What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.